Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkHospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance

In a study of parenteral cancer drug pricing at 61 NCI-designated cancer centers, median price markups on 25 commonly used drugs ranged from approximately 120% to 630% over acquisition cost. The paper’s authors recommend public policy prohibiting excessive markup on parenteral chemotherapies as a means to reduce unnecessary financial burden on patients.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form